• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性淋巴细胞白血病（CLL）患者中与阿卡拉布替尼相关的第二原发性恶性肿瘤和非黑色素瘤皮肤癌：随机对照试验（RCT）的系统评价和荟萃分析。

Acalabrutinib-related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta-analysis of randomised controlled trials (RCTs).

作者信息

Htut Thura W, Han Myat M, Thein Kyaw Z

机构信息

Department of Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen United Kingdom.

Division of Hematology and Medical Oncology Oregon Health and Science University/ Knight Cancer Institute Portland Oregon United States.

出版信息

EJHaem. 2020 Dec 4;2(1):112-117. doi: 10.1002/jha2.146. eCollection 2021 Feb.

DOI:10.1002/jha2.146
PMID:35846092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9175848/
Abstract

Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta-analysis of randomised controlled trials to determine the risks of acalabrutinib-related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person-years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person-years in the acalabrutinib group versus 1.12 per 100 person-years in the control group (RR 2.43). Long-term follow-up and future studies are necessary to define the actual relationship and their risk factors.

摘要

阿卡拉布替尼是第二代布鲁顿酪氨酸激酶抑制剂，最近被批准用于治疗慢性淋巴细胞白血病。我们对随机对照试验进行了系统评价和荟萃分析，以确定阿卡拉布替尼相关的第二原发性恶性肿瘤（SPM）和非黑色素瘤皮肤癌（NMSC）的风险。与对照组相比，阿卡拉布替尼组的SPM发生率高4.7%，风险比（RR）为1.76（每100人年5.32例 vs 3.2例）。值得注意的是，NMSC是最常见的SPM，阿卡拉布替尼组的发生率为每100人年2.56例，而对照组为每100人年1.12例（RR 2.43）。需要长期随访和未来研究来确定实际关系及其危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/e41d8fecb630/JHA2-2-112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/b1cefac10e3c/JHA2-2-112-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/d13217368e6a/JHA2-2-112-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/72219d9024aa/JHA2-2-112-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/d7c0823c311f/JHA2-2-112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/3c5b3d6a4b8b/JHA2-2-112-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/09d40e00d4b4/JHA2-2-112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/87a520d0ca89/JHA2-2-112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/e41d8fecb630/JHA2-2-112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/b1cefac10e3c/JHA2-2-112-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/d13217368e6a/JHA2-2-112-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/72219d9024aa/JHA2-2-112-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/d7c0823c311f/JHA2-2-112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/3c5b3d6a4b8b/JHA2-2-112-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/09d40e00d4b4/JHA2-2-112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/87a520d0ca89/JHA2-2-112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41cd/9175848/e41d8fecb630/JHA2-2-112-g001.jpg

相似文献

1
Acalabrutinib-related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta-analysis of randomised controlled trials (RCTs).慢性淋巴细胞白血病（CLL）患者中与阿卡拉布替尼相关的第二原发性恶性肿瘤和非黑色素瘤皮肤癌：随机对照试验（RCT）的系统评价和荟萃分析。
EJHaem. 2020 Dec 4;2(1):112-117. doi: 10.1002/jha2.146. eCollection 2021 Feb.
2
Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials.慢性淋巴细胞白血病患者中与阿卡拉布替尼相关的心脏毒性：随机对照试验的荟萃分析
J Immunother Precis Oncol. 2021 Nov 4;5(2):43-47. doi: 10.36401/JIPO-21-12. eCollection 2022 May.
3
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.STELLAR 试验方案：一项新诊断 RS 患者接受 CHOP-R 联合或不联合阿卡替尼的随机试验调查，以及复发疾病中新型药物评估的单臂平台研究组成的 Richter 综合征前瞻性多中心试验
BMC Cancer. 2019 May 20;19(1):471. doi: 10.1186/s12885-019-5717-y.
4
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
5
Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.阿卡拉布替尼，第二代布鲁顿酪氨酸激酶抑制剂。
Recent Results Cancer Res. 2018;212:285-294. doi: 10.1007/978-3-319-91439-8_14.
6
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.评估阿卡替尼在治疗慢性淋巴细胞白血病中的药代动力学。
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1023-1030. doi: 10.1080/17425255.2021.1955855. Epub 2021 Jul 28.
7
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.阿卡替尼与研究者选择方案治疗复发/难治性慢性淋巴细胞白血病：ASCEND试验最终结果
Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec.
8
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.阿卡替尼单药治疗慢性淋巴细胞白血病（ACE-CL-001）：一项开放标签、单臂、1-2 期研究中 Richter 转化队列的分析。
Lancet Haematol. 2021 Dec;8(12):e912-e921. doi: 10.1016/S2352-3026(21)00305-7. Epub 2021 Nov 1.
9
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.阿卡拉布替尼及其在慢性淋巴细胞白血病治疗中的治疗潜力：关于新出现数据的简短综述
Cancer Manag Res. 2020 Mar 19;12:2079-2085. doi: 10.2147/CMAR.S219570. eCollection 2020.
10
An update on acalabrutinib to treat chronic lymphocytic leukemia.阿卡替尼治疗慢性淋巴细胞白血病的最新进展。
Drugs Today (Barc). 2021 Jul;57(7):417-431. doi: 10.1358/dot.2021.57.7.3285932.

引用本文的文献

1
Aberrant Expression of , , , , and in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers.与健康志愿者相比，慢性淋巴细胞白血病和银屑病患者中[具体基因名称]、[具体基因名称]、[具体基因名称]、[具体基因名称]、[具体基因名称]和[具体基因名称]的异常表达
Cancers (Basel). 2025 Jun 24;17(13):2116. doi: 10.3390/cancers17132116.
2
Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies.使用布鲁顿酪氨酸激酶抑制剂治疗血液系统恶性肿瘤后发生的葡萄膜黑色素瘤。
Am J Ophthalmol Case Rep. 2025 May 3;38:102345. doi: 10.1016/j.ajoc.2025.102345. eCollection 2025 Jun.
3
Squamous cell carcinoma arising in a below-knee stump of a patient with chronic lymphocytic leukemia.

本文引用的文献

1
Second cancer incidence in CLL patients receiving BTK inhibitors.慢性淋巴细胞白血病患者接受 BTK 抑制剂治疗后的二次癌症发病情况。
Leukemia. 2020 Dec;34(12):3197-3205. doi: 10.1038/s41375-020-0987-6. Epub 2020 Jul 23.
2
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
3
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
一名慢性淋巴细胞白血病患者的膝下残肢发生鳞状细胞癌。
J Vasc Surg Cases Innov Tech. 2024 May 21;10(4):101537. doi: 10.1016/j.jvscit.2024.101537. eCollection 2024 Aug.
初治方案对 CLL 患者第二原发恶性肿瘤和 Richter 转化的影响。
Leukemia. 2016 Oct;30(10):2019-2025. doi: 10.1038/leu.2016.113. Epub 2016 May 2.
4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.阿卡替尼（ACP-196）用于复发的慢性淋巴细胞白血病
N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.
5
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
6
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).布鲁顿酪氨酸激酶（BTK）的功能对慢性淋巴细胞白血病（CLL）的发展和扩张很重要。
Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.
7
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.系统评价与Meta分析优先报告条目：PRISMA声明
PLoS Med. 2009 Jul 21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
8
Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice.慢性淋巴细胞白血病的内在及治疗相关免疫改变及其对临床实践的影响。
Expert Opin Pharmacother. 2008 Jun;9(9):1481-94. doi: 10.1517/14656566.9.9.1481.
9
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.慢性淋巴细胞白血病（CLL）患者亚群中不同BCR信号通路的组成性激活：一种无反应性的分子特征。
Blood. 2008 Jul 1;112(1):188-95. doi: 10.1182/blood-2007-09-111344. Epub 2008 Feb 21.
10
Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death.患有慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的退伍军人发生第二种恶性肿瘤的几率显著增加，这是最常见的死亡原因。
Leuk Lymphoma. 2004 Mar;45(3):507-13. doi: 10.1080/10428190310001612939.